Welcome to our dedicated page for Ispecimen news (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on Ispecimen stock.
iSpecimen Inc. (NASDAQ: ISPC) generates a steady flow of company-specific news that reflects both its role in life science research and its activities in the capital markets. Public announcements consistently describe iSpecimen as an online global marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with hospitals, labs, biobanks, blood centers and other healthcare providers that have access to patients and specimens needed for medical discovery.
News related to ISPC frequently covers financing and capital-raising transactions. Recent press releases describe underwritten public offerings, private placements of common stock and pre-funded warrants, and the issuance of preferred stock, along with intended uses of proceeds such as marketing, working capital, and payments under agreements with service providers and technology partners. These items are often accompanied by references to related SEC filings, such as registration statements on Form S-1 and current reports on Form 8-K.
Operational and strategic updates form another key category of iSpecimen news. The company has announced initiatives to expand services for high-demand cancer biospecimens, including plans to pursue partnerships with U.S.-based cancer centers and to act as a preferred provider of cancer biospecimens in collaboration with an international genomic sequencing partner. Other releases highlight the company’s ability to secure suppliers for specimens related to emerging infectious diseases, such as human metapneumovirus, illustrating how its marketplace can respond to evolving research needs.
Technology and infrastructure developments are also prominent in iSpecimen’s news flow. The company has reported milestones in a digital transformation program powered by the Salestack platform, describing the installation of modern, cloud-native infrastructure to enhance the iSpecimen Marketplace. In addition, iSpecimen has issued detailed announcements about a corporate treasury strategy focused on digital assets and the Solana blockchain ecosystem, including advisory relationships with WestPark Capital and BlockArrow.
Governance and listing-related disclosures appear in both press releases and SEC-linked news, such as notices from Nasdaq regarding listing standards, special and annual stockholder meetings, and leadership changes at the executive and board levels. Together, these updates provide investors and researchers with insight into iSpecimen’s marketplace activities, strategic direction, financing plans, and regulatory interactions. Visitors to the ISPC news page can review this evolving record of announcements to understand how the company is positioning its biospecimen marketplace and managing its public-company obligations.
iSpecimen (NASDAQ: ISPC) announced completion of Milestone 2: System Integration and Marketplace Activation on February 6, 2026, delivering a live SalesStack production marketplace. Key achievements include end-to-end system integration, full legacy data migration, core feature enablement, AI-assisted matching, and launch of a production site at https://mp.ispecimen.com.
Company says the update enables operational continuity, cost reductions from legacy sunset, improved scalability and performance, and a foundation for supplier onboarding, pricing automation, and broader rollouts ahead of Milestone 3.
iSpecimen (NASDAQ: ISPC) reported a rapid procurement milestone on February 6, 2026, collecting 500 influenza swab samples in a few weeks to support a customer research project. The company also reports steady supply of cerebrospinal fluid (CSF) and rising demand for FFPE and fresh frozen tissue specimens. Customer feedback praised specimen quality and documentation for a 20-sample urine shipment and indicated intent to cite iSpecimen as the sample source in publications, underlining continued customer engagement and confidence.
iSpecimen (Nasdaq: ISPC) announced a private placement expected to raise approximately $5.5 million in gross proceeds through the issuance of 6,875 shares of newly designated Series C Convertible Preferred Stock at $800 per share.
Each preferred share has a $1,000 stated value and converts into common stock at a conversion price equal to 85% of the closing price of common stock on the trading day before each conversion date. The company intends to use net proceeds for marketing, working capital, and general corporate purposes. Closing is expected on or about December 31, 2025, subject to customary conditions. E.F. Hutton is the exclusive placement agent. The securities are offered in a private placement to accredited investors and the company agreed to file registration statements covering resale of conversion shares.
iSpecimen (NASDAQ: ISPC) has provided an update on its strategic initiative to integrate digital assets into its business model. The company is pursuing the development of a $200 million corporate treasury reserve based on the Solana blockchain ecosystem. Since its August announcement, ISPC has received approaches from several cryptocurrency companies presenting opportunities in tokenized real-world assets and highly ranked cryptocurrencies.
Under CEO Robert Lim's leadership, iSpecimen plans to establish a SOL-based treasury program to diversify its balance sheet and support long-term growth. The company intends to implement a "buy and HODL" strategy, including purchasing Locked SOL at a discount and utilizing staking mechanisms to generate yields. The program will be funded through future capital raises and will include the acquisition of both locked and unlocked SOL through reputable cryptocurrency institutions.
iSpecimen (NASDAQ: ISPC), a human biospecimens marketplace, has completed Milestone 1 of its digital transformation program with Salestack Solutions. The milestone involves implementing Salestack's cloud-native platform to modernize the iSpecimen Marketplace® infrastructure.
Key improvements include Infrastructure-as-Code (IaC), unified storage and workflows, and a future-ready foundation supporting multi-cloud deployment. The upgrade provides automated security, improved reliability, and faster development cycles. This completion sets the stage for Milestone 2 (Integration), which will focus on connecting all business operations to the Salestack platform.
iSpecimen (NASDAQ: ISPC) has announced plans to establish a $200 million corporate treasury built around Solana cryptocurrency. The biospecimen technology company has partnered with BlockArrow, a digital asset advisory firm, and WestPark Capital to guide this strategic initiative.
The treasury will leverage Solana's blockchain ecosystem, chosen for its high throughput, low transaction costs, and enterprise security features. BlockArrow will implement a layered security model including offline cold storage and insured custody through Coinbase Custody, backed by Lloyd's of London.
This strategic move represents iSpecimen's commitment to integrating digital assets into its business model and positioning itself as a leader in blockchain adoption within the life sciences sector.
iSpecimen (Nasdaq: ISPC), an online marketplace for biospecimens, has completed a $1.75 million private placement of common stock and pre-funded warrants. The company issued 1,559,828 shares at $1.122 per share, priced at-the-market under Nasdaq rules.
Of the net proceeds, $500,000 will be allocated to marketing and advertising services through IR Agency LLC, with the remainder supporting working capital and general corporate purposes. WestPark Capital served as the exclusive placement agent for the offering, which closed on August 4, 2025.
iSpecimen (Nasdaq: ISPC), an online marketplace for biospecimens, has announced a $1.75 million private placement of securities priced at-the-market. The company will issue 1,559,828 shares of common stock (or pre-funded warrants) at $1.122 per share.
The offering, expected to close around August 1, 2025, will be placed through WestPark Capital, Inc. Of the proceeds, $500,000 will be allocated to marketing services through IR Agency LLC, with the remainder used for working capital and general corporate purposes. The securities are being offered exclusively to accredited investors and will require registration with the SEC for resale.
iSpecimen (Nasdaq: ISPC) has successfully closed its previously announced underwritten public offering, raising approximately $4 million through the sale of 5,714,283 shares of common stock at $0.70 per share. The biospecimen marketplace company plans to allocate $1.5 million for marketing services through IR Agency LLC and $1 million for an initial milestone payment to Sales Stack Solutions Corp., with the remainder designated for working capital.
WestPark Capital, Inc. served as the Sole Book-Runner for this firm commitment offering, which was conducted under an effective S-1 registration statement. This press release corrects an earlier version that incorrectly listed KCSA Strategic Communications as iSpecimen's investor relations contact.
iSpecimen (Nasdaq: ISPC), an online marketplace for biospecimens, has announced the pricing of an underwritten public offering of 5,714,283 shares at $0.70 per share, aiming to raise approximately $4 million in gross proceeds.
The company plans to allocate $1.5 million for marketing services through IR Agency LLC, $1 million for an initial milestone payment to Sales Stack Solutions Corp., and the remainder for working capital. WestPark Capital is serving as the Sole Book-Runner, with the offering expected to close on July 25, 2025.